LEADER 03096nam  2200673Ia 450 
001 9910827752803321
005 20240410135120.0
010   $a6610810575
010   $a1-280-81057-2
010   $a9786610810574
010   $a1-4294-6773-8
010   $a1-60750-222-4
010   $a600-00-0360-9
010   $a1-4337-0156-1
035   $a(CKB)1000000000340130
035   $a(EBL)287004
035   $a(OCoLC)347009849
035   $a(SSID)ssj0000117837
035   $a(PQKBManifestationID)11143710
035   $a(PQKBTitleCode)TC0000117837
035   $a(PQKBWorkID)10049304
035   $a(PQKB)11024286
035   $a(MiAaPQ)EBC287004
035   $a(Au-PeEL)EBL287004
035   $a(CaPaEBR)ebr10167405
035   $a(CaONFJC)MIL81057
035   $a(EXLCZ)991000000000340130
100   $a20061127d2006      uy         0
101 0 $aeng
135   $aur|n|---|||||
181   $ctxt
182   $cc
183   $acr
200 00$aCardiovascular benefits of omega-3 polyunsaturated fatty acids$b[electronic resource] /$fedited by B. Maisch and  R. Oelze
205   $a1st ed.
210   $aAmsterdam ;$aWashington, DC $cIOS Press$dc2006
215   $a1 online resource (196 p.)
225 1 $aSolvay Pharmaceuticals Conferences ;$vv. 7
300   $aHeld during the European Cardiology Society Congress in Stockholm in 2005.
311   $a1-58603-707-2 
320   $aIncludes bibliographical references and index.
327   $aTitle page; Preface; List of Contributors; Contents; Conference Preface; Keynote Lecture - Risk Factors for Atherosclerotic Disease: Present and Future; Microdetermination of Fatty Acids by Gas Chromatography and Cardiovascular Risk Stratification by the ""EPA+DHA Level""; Highly Purified Omega-3 Polyunsaturated Fatty Acids Are Effective as Adjunct Therapy for Secondary Prevention of Myocardial Infarction: Critical Analysis of GISSI-Prevenzione Trial; Prevention of Cardiovascular Diseases and Highly Concentrated n-3 Polyunsaturated Fatty Acids (PUFAs)
327   $aOmega-3 Fatty Acids and Sudden Arrhythmic DeathDepression and Coronary Artery Disease: Epidemiology and Potential Mechanisms; Effects of Omega-3 Polyunsaturated Fatty Acids on Depression; A Multi-Country Health-Economic Evaluation of Highly Concentrated n-3 Polyunsaturated Fatty Acids (PUFAs) in the Secondary Prevention After Myocardial Infarction (MI); OMACOR® in Clinical Development: A Survey of Current Trials; Author Index
330   $aSolvay Pharmaceuticals Conferences
410  0$aSolvay Pharmaceuticals Conferences ;$vv. 7.
606   $aHeart$xDiseases$vCongresses
606   $aOmega-3 fatty acids$xTherapeutic use$vCongresses
615  0$aHeart$xDiseases
615  0$aOmega-3 fatty acids$xTherapeutic use
676   $a613.2/84
701   $aMaisch$b Bernhard$01659401
701   $aOelze$b R$01659402
801  0$bMiAaPQ
801  1$bMiAaPQ
801  2$bMiAaPQ
906   $aBOOK
912   $a9910827752803321
996   $aCardiovascular benefits of omega-3 polyunsaturated fatty acids$94014002
997   $aUNINA